Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study [PDF]
, 2012 Background: Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver damage, may determine survival in clinical end-stage liver disease.
Bachmann, Malte +11 more
core +1 more source
Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies [PDF]
, 2017 Background The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available.
Araya, V. +11 more
core +2 more sources
Hepatology, 1997 Chronic alcoholism in patients with chronic hepatitis C appears to cause more severe and rapidly progressive liver disease leading more frequently to cirrhosis of the liver and hepatocellular carcinoma. The primary risk factor for acquiring hepatitis C among alcoholics is injection drug use.
openaire +2 more sources
The SGOT/SGPT ratio in alcoholic liver disease.
Acta Médica Portuguesa, 1981 The SGOT/SGPT ratio has been estimated in 207 patients with alcoholic liver disease and in 3 control groups (43 viral hepatitis, 30 non-alcoholic chronic liver disease and 42 obstructive jaundice).
Patrícia S. Alves +2 more
doaj +1 more source
Comparative Study of 5’- Nucleotidase Test in Various Liver Diseases [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: The liver regulates many important metabolic functions. The 5’-nucleotidase activity is increased in obstructive jaundice, parenchymal liver disease, and hepatic metastases. Aim: This study was conducted to assess the serum levels of 5’-
Mohd Azam Hyder +2 more
doaj +1 more source
The effect of 12 weeks regular physical activity and vitamin E in the treatment of non-alcoholic steatohepatitis: A pilot study [PDF]
, 2015 Background: Despite the prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), there was no treatment has been proven to be effective in these common diseases.
Eslami, L. +5 more
core +7 more sources
Lipid-bound sialic acid (LSA) in liver diseases of different etiologies
Annals of Hepatology, 2011 Objective. There are evidences that the changes in glycosylation and sialylation of proteins and lipids play an important role in the pathogenesis and progression of various liver diseases.
Lech Chrostek +4 more
doaj +1 more source
Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options
Cell Adhesion & Migration, 2023 Hepatocellular carcinoma (HCC) is the seventh most highly prevalent malignant tumor globally and the second most common cause of mortality. HCC develops with complex pathways that occur through multistage biological processes.
Sugan Panneerselvam +6 more
doaj +1 more source
Gut Microbes, 2020 Background and Aims Alcoholic hepatitis is the most severe form of alcohol-related liver disease. While the gut microbiome is known to play a role in disease development and progression, less is known about specific compositional changes of the gut ...
Sonja Lang +6 more
doaj +1 more source
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]
, 2019 Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence +2 more
core +2 more sources